Superluminal Medicines Inc.
Mark Fitzgerald serves as the Director of Chemistry at Superluminal Medicines Inc. since October 2024. Prior experience includes roles at Nested Therapeutics as Chemistry Consultant and Director of Chemistry, where Mark contributed significantly to allosteric inhibitor and protein-protein interaction disruption projects in oncology. At C4 Therapeutics, Mark held the position of Associate Director of Chemistry, managing external teams and participating in lead optimization projects. Previous positions at the Broad Institute involved leading chemistry efforts on cancer-targeted projects and antibacterials, while initial roles included research positions at Pamlico Pharmaceutical Inc., 3-Dimensional Pharmaceuticals, and Provid Research, focusing on various therapeutic areas. Mark holds a B.A. in Chemistry from Rutgers University and a PhD in Organic Chemistry from the University of Pennsylvania.
This person is not in any teams
Superluminal Medicines Inc.
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.